semaglutide therapy Trial suggests GLP-1 combo cuts fat while preserving muscle in obesity Semaglutide Therapy in Phoenix AZ

Ongoing Support: Enjoy free monthly check-ins with our experienced surgeon, ensuring you stay on track and receive the guidance you need

Posts are sponsored in part by the retailers and/or brands listed on this page.

Scientific and Official Sources Eli Lilly: What to know about Retatrutide and its investigational status Coskun T and colleagues: LY3437943, a novel triple GIP, GLP 1 and glucagon receptor agonist Jastreboff AM and colleagues: Triple hormone receptor agonist Retatrutide for obesity ClinicalTrials.gov: Retatrutide Phase 3 obesity and overweight programme Bajaj HS and colleagues: Phase 3 Retatrutide research in type 2 diabetes ClinicalTrials.gov: Retatrutide compared with Tirzepatide MHRA: Borderline products and how to tell if a product is a medicine MHRA Guidance Note 8: A guide to what is a medicinal product Human Medicines Regulations 2012: Regulation 279 ASA, MHRA and GPhC warning on promoting unlicensed pipeline weight management medicines MHRA: May 2026 seizure involving unlicensed Retatrutide and other products The Human Medicines Regulations 2012 Health and Safety Executive: UK REACH Health and Safety Executive: Safety Data Sheets Health and Safety Executive: COSHH risk assessment

This would include deep integration of nutrition as therapy

The relationship between central adrenal insufficiency and sleep-related breathing disorders in children with Prader-Willi syndrome

According to FDA prescribing information, injection site reactions occur in approximately 1.4% of patients using Ozempic and 2.4% of patients using Wegovy